RxDoctor Payments Data

Rebecca Smith, MD

Cardiovascular Disease · Cape Girardeau, MONPI 1083684583

Payments from drug & device makers

$6,927in general payments, 2019–2025

Across 219 payments — averaging $31.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Edwards Lifesciences$2K
  • Novartis$805
  • Amgen$421
  • Johnson & Johnson$396
  • Boston Scientific$383
  • plus $1K from 17 others

What the payments were for

  • Speaking & faculty fees$6009%
  • Travel & lodging$1,33219%
  • Food & beverage$4,87470%
  • Education$1212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,927 in reported general payments places this provider in the 65th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$203,689
Medicare patients
2,150
Services billed
4,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban316$265,708
EntrestoSacubitril/Valsartan162$146,997
XareltoRivaroxaban120$92,282
Repatha SureclickEvolocumab19$10,640
Praluent PenAlirocumab14$7,113
Metoprolol Succinate372$4,762
VascepaIcosapent Ethyl12$4,209
Propafenone Hcl ErPropafenone Hcl21$2,560
Potassium Chloride107$1,908
Flecainide Acetate25$1,587
ClopidogrelClopidogrel Bisulfate257$1,251
Propafenone Hcl38$1,251
Atorvastatin Calcium176$1,232
Furosemide308$1,153
Diltiazem 24hr Er (Cd)Diltiazem Hcl61$1,141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$173$265,708316 claims
NovartisEntresto$805$146,997162 claims
Johnson & JohnsonXarelto$396$92,282120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Cape Girardeau

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →